BRPI0809651A2 - Agonistas de kappa-opiato para o tratamento de síndrome do cólon irritável de diarreia predominante ou alternada - Google Patents

Agonistas de kappa-opiato para o tratamento de síndrome do cólon irritável de diarreia predominante ou alternada

Info

Publication number
BRPI0809651A2
BRPI0809651A2 BRPI0809651-1A2A BRPI0809651A BRPI0809651A2 BR PI0809651 A2 BRPI0809651 A2 BR PI0809651A2 BR PI0809651 A BRPI0809651 A BR PI0809651A BR PI0809651 A2 BRPI0809651 A2 BR PI0809651A2
Authority
BR
Brazil
Prior art keywords
irritable
alternated
kappa
diarrhea
predominant
Prior art date
Application number
BRPI0809651-1A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Allen Mangel
Original Assignee
Tioga Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tioga Pharmaceuticals Inc filed Critical Tioga Pharmaceuticals Inc
Publication of BRPI0809651A2 publication Critical patent/BRPI0809651A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
BRPI0809651-1A2A 2007-03-30 2008-03-07 Agonistas de kappa-opiato para o tratamento de síndrome do cólon irritável de diarreia predominante ou alternada BRPI0809651A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92084107P 2007-03-30 2007-03-30
PCT/US2008/056317 WO2008121496A1 (en) 2007-03-30 2008-03-07 Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome

Publications (1)

Publication Number Publication Date
BRPI0809651A2 true BRPI0809651A2 (pt) 2014-10-07

Family

ID=39795494

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809651-1A2A BRPI0809651A2 (pt) 2007-03-30 2008-03-07 Agonistas de kappa-opiato para o tratamento de síndrome do cólon irritável de diarreia predominante ou alternada

Country Status (19)

Country Link
US (2) US7960429B2 (enExample)
EP (3) EP2561870A1 (enExample)
JP (2) JP5416085B2 (enExample)
KR (2) KR101208326B1 (enExample)
CN (2) CN102641265A (enExample)
AU (1) AU2008232954A1 (enExample)
BR (1) BRPI0809651A2 (enExample)
CA (1) CA2682608A1 (enExample)
CY (1) CY1113317T1 (enExample)
DK (1) DK2136801T3 (enExample)
ES (1) ES2393815T3 (enExample)
HR (1) HRP20120798T1 (enExample)
IL (1) IL201226A0 (enExample)
MX (1) MX2009010409A (enExample)
PL (1) PL2136801T3 (enExample)
PT (1) PT2136801E (enExample)
RU (1) RU2441655C2 (enExample)
SI (1) SI2136801T1 (enExample)
WO (1) WO2008121496A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2136801T3 (da) * 2007-03-30 2012-12-17 Tioga Pharmaceuticals Inc Kappa-opiat-agonister til behandling af diarré-dominerende og afvekslende irritabel tarmsyndrom
WO2012012410A2 (en) * 2010-07-19 2012-01-26 Dr. Reddy's Laboratories Ltd. Kappa opioid receptor agonists
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
CA3178035A1 (en) 2012-12-24 2014-07-03 Neurogastrx, Inc. Methods for treating gi tract disorders
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine
JP6410641B2 (ja) 2015-03-04 2018-10-24 ローム株式会社 ワイヤレス送電装置、異物検出方法、充電器
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
WO2018119108A1 (en) 2016-12-21 2018-06-28 Tioga Pharmaceuticals Inc. Splid pharmaceutical formulations of asimadoline
WO2019122361A1 (en) 2017-12-22 2019-06-27 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis
IL318587A (en) 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
JP2023518711A (ja) * 2020-03-18 2023-05-08 カラ セラピューティクス インコーポレイテッド κオピオイド受容体作動薬のオリゴ糖製剤
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline
JP7464744B2 (ja) * 2020-10-20 2024-04-09 セトラスホールディングス株式会社 診療支援装置、診療支援方法、診療支援プログラム及び診療支援システム
WO2022155332A1 (en) * 2021-01-13 2022-07-21 Blue Therapeutics, Inc. Methods of treating irritable bowel syndrome

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192883A (en) * 1976-04-09 1980-03-11 Pierre Fabre, S.A. Amides of pyrrolidinoethylamine which can be used in lung therapy
FR2421891A1 (fr) 1977-10-17 1979-11-02 Fabre Sa Pierre Obtention industrielle d'amides de la pyrrolidine ethyl amine
US4663343A (en) * 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4760069A (en) * 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
GB8601796D0 (en) * 1986-01-24 1986-02-26 Zambeletti Spa L Compounds
JPH02138254A (ja) 1988-02-23 1990-05-28 Glaxo Group Ltd 複素環誘導体
DE4034785A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE3935371A1 (de) 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
US5389686A (en) * 1989-02-20 1995-02-14 Jouveinal Sa Analgesic properties of fedotozine
DE3916663A1 (de) * 1989-05-23 1990-11-29 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-acyl-sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
CA2021817C (en) * 1989-07-24 2000-09-26 William J. Mork Upholstered article of furniture with interchangeable seating module
JPH05501551A (ja) 1989-11-24 1993-03-25 スミスクライン　ビーチャム　ファルマシューティッチ　エッセ　ピ　ア アザ環式誘導体
GB8926560D0 (en) 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
US5300687A (en) 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
DE4215213A1 (de) 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4425071C2 (de) * 1994-07-15 1996-08-29 Degussa Verfahren zur Herstellung optisch aktiver Pyrrolidine mit hoher Enantiomerenreinheit
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
ATE314092T1 (de) 1997-09-26 2006-01-15 Noven Pharma Biologische kleber und verfahren zur topischen verabreichung von wirkstoffen
US20010051181A1 (en) * 1997-12-22 2001-12-13 Van Osdol William W. Novel formulations for the transdermal administration of asimadoline
DE19827633A1 (de) 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
DK1093370T3 (da) * 1998-06-30 2006-05-22 Takeda Pharmaceutical Farmaceutisk præparat til behandling af diabetes
JP2000080047A (ja) 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
DE19849650A1 (de) 1998-10-29 2000-05-04 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung des Irritable Bowel Syndroms (IBS)
PT1033364E (pt) 1999-03-01 2005-07-29 Pfizer Prod Inc Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
GB0015562D0 (en) 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US20020025948A1 (en) * 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
US6846831B2 (en) * 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
DE10116978A1 (de) 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
US6780891B2 (en) 2001-11-30 2004-08-24 Sepracor Inc. Tramadol analogs and uses thereof
JP2005531557A (ja) * 2002-05-17 2005-10-20 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 選択的オピエート受容体モジュレーターとして効果的な化合物の使用
JP2006502190A (ja) * 2002-09-18 2006-01-19 ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ デルタ−オピオイド受容体に選択的なオピエート類似物
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
EP1617846A1 (en) 2003-04-08 2006-01-25 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
BRPI0409133B8 (pt) * 2003-04-08 2021-05-25 Progenics Pharm Inc preparações farmacêuticas estavéis compreendendo metilnaltrexona
DK1644021T3 (da) * 2003-06-13 2012-10-29 Ironwood Pharmaceuticals Inc Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
WO2005046687A1 (en) * 2003-10-30 2005-05-26 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
DK2136801T3 (da) * 2007-03-30 2012-12-17 Tioga Pharmaceuticals Inc Kappa-opiat-agonister til behandling af diarré-dominerende og afvekslende irritabel tarmsyndrom

Also Published As

Publication number Publication date
KR20100016004A (ko) 2010-02-12
EP2136801A4 (en) 2010-05-26
DK2136801T3 (da) 2012-12-17
PL2136801T3 (pl) 2013-01-31
SI2136801T1 (sl) 2013-01-31
JP2010523492A (ja) 2010-07-15
CN102641265A (zh) 2012-08-22
US7960429B2 (en) 2011-06-14
CY1113317T1 (el) 2016-04-13
US20110046174A1 (en) 2011-02-24
KR101208326B1 (ko) 2012-12-05
US8877800B2 (en) 2014-11-04
PT2136801E (pt) 2012-12-06
AU2008232954A2 (en) 2011-12-01
JP2013173790A (ja) 2013-09-05
JP5416085B2 (ja) 2014-02-12
CN101677997B (zh) 2012-05-09
ES2393815T3 (es) 2012-12-28
HK1139860A1 (en) 2010-09-30
IL201226A0 (en) 2010-05-31
EP2561870A1 (en) 2013-02-27
AU2008232954A1 (en) 2008-10-09
KR101263225B1 (ko) 2013-05-13
RU2441655C2 (ru) 2012-02-10
EP2136801A1 (en) 2009-12-30
HRP20120798T1 (hr) 2012-11-30
EP2636407A3 (en) 2013-11-06
MX2009010409A (es) 2010-03-29
CN101677997A (zh) 2010-03-24
KR20120058614A (ko) 2012-06-07
EP2636407A2 (en) 2013-09-11
US20080242720A1 (en) 2008-10-02
CA2682608A1 (en) 2008-10-09
RU2009140042A (ru) 2011-05-10
EP2136801B1 (en) 2012-08-29
WO2008121496A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
BRPI0809651A2 (pt) Agonistas de kappa-opiato para o tratamento de síndrome do cólon irritável de diarreia predominante ou alternada
NL301192I2 (nl) Finerenon en zijn zouten, solvaten en solvaten van de zouten daarvan
PT2034844T (pt) Método para o tratamento de síndrome do intestino irritável com predominância de diarreia
PT2514436T (pt) Il-22 para utilização no tratamento de distúrbios microbianos
BRPI0813449A2 (pt) Formas de dosagem sólida ou semissólida de liberação modificada.
BRPI1015262A2 (pt) inibidores de pl3 quinase e/ou motor
BRPI0911923A2 (pt) dispositivos filamentosos para o tratamento de defeitos vasculares
BRPI0808422A2 (pt) Compostos orgânicos bicíclicos adequados para o tratamento de condições inflamatórias ou alérgicas
BRPI0820153A2 (pt) Aperfeiçoamento de ação direta para rifles
BRPI0913129A2 (pt) método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
BRPI0921237A2 (pt) métodos e composições para o tratamento de distúrbios associados ao complemento
EP2076492A4 (en) NON-NUCLEOSIDIC REVERSE TRANSCRIPTASE INHIBITORS
HRP20181727T1 (hr) Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška
EP2217069A4 (en) INHIBITORS OF NON-NUCLEOSIDE INHIBITORS OF THE REVERSE TRANSCRIPTASE
BRPI0911083A2 (pt) métodos para o tratamento ou prenvenção de diabetes mullitus e outros desequilíbrios metabólicos
BRPI0807377A2 (pt) Uso de rosiglitazona, 5-asa ou compostos, métodos para identificar agentes antiinflamatórios e/ou antimicrobianos, e para identificar agentes antiinflamatórios e antibacterianos potenciais, e, composição
BRPI0921087A2 (pt) válvula para utilização universal e diversas finalidades
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
BRPI0923567A2 (pt) agentes antibactericidas novos para o tratamento de infecções gram positivas
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
DOP2010000373A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
EP2174986A4 (en) THERMAL TREATMENT OIL COMPOSITION
BRPI0921079A2 (pt) métodos para minimizar a perda de fluidos e para determinar a localização de zonas de circulação perdida.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2367 DE 17-05-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.